42
Newsletter Signup – Under Article / In Page
“*” indicates required fields
The European Society for Medical Oncology(ESMO) Congress 2025 in Berlin (17–21 October) delivered a week of consequential but not always uniform readouts. Antibody-drug conjugates (ADCs) stayed in the spotlight, most notably with disitamab vedotin in first-line, HER2-expressing urothelial cancer.
Radiopharmaceuticals advanced but with caveats:…